Role of modulation of vascular endothelial growth factor and tumor necrosis factor-alpha in gastric ulcer healing in diabetic rats.
The aim of the present study was to assess the effect of drugs that increase gastric vascular endothelial growth factor (VEGF) and suppress gastric tumor necrosis factor-alpha (TNF-alpha) in gastric ulcer healing in streptozotocin-induced diabetic rats. Sixty male albino rats were made diabetic by intraperitoneal (i.p.) streptozotocin injection and ten rats were injected i.p. by a single dose of saline. Six weeks following streptozotocin or saline injection, gastric ulcers were induced by serosal application of acetic acid. Three days after acetic acid application, rats were divided into: group I (non-diabetic control), group II (streptozotocin-injected), groups III-VII (streptozotocin-injected rats treated with insulin, insulin and pentoxifylline, insulin and simvastatin, pentoxifylline as well as simvastatin, respectively, for 7 days following acetic acid application. The use of insulin, combinations of insulin and pentoxifylline or simvastatin resulted in a significant decrease in gastric ulcer area, significant increase in epithelial regeneration assessed histologically, significant increase in gastric VEGF concentration, and gastric von Willebrand factor (vWF) as well as significant decrease in gastric TNF-alpha. A significant difference in gastric ulcer area as well as in gastric TNF-alpha, VEGF and vWF levels could be observed between rats that received combinations of insulin and pentoxifylline or simvastatin compared to rats that received either drug alone. Our results suggest the feasibility of a novel treatment strategy, namely pentoxifylline and simvastatin, for patients in whom impairment of ulcer healing constitutes a secondary complication of diabetes mellitus.
Baraka
Azza M
AM
Pharmacology Dept, Alexandria University, Egypt. mnhbaraka@yahoo.com
Guemei
Aida
A
Gawad
Hala Abdel
HA
D019342:Acetic Acid; D000818:Animals; D000924:Anticholesteremic Agents; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000188:drug therapy; D016166:Free Radical Scavengers; D007328:Insulin / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010431:Pentoxifylline / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy*; D013311:Streptozocin; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000187:drug effects*; D014945:Wound Healing / Q000187:drug effects*
D000924:Anticholesteremic Agents; D016166:Free Radical Scavengers; D007328:Insulin; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D013311:Streptozocin; D019821:Simvastatin; D019342:Acetic Acid; D010431:Pentoxifylline